Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Gilles Edan(Centre National de la Recherche Scientifique), Jean‐Louis Herrmann(Inserm), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Brigitte Stemper(Bayer (Germany)), Ludwig Kappos(University Hospital of Basel), Christoph Pohl, Hans‐Peter Hartung(The University of Sydney), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Vivian Lanius(Bayer (Germany)), Rupert Sandbrink(Io Therapeutics (United States)), Mark S. Freedman, David Miller, Dirk Pleimes, Chris H. Polman(Vrije Universiteit Amsterdam)
Cited by 82
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k